Fda Panel Advisor Who Panned New Alzheimer’s Drug Speaks Out
An external guide to the U.S. Food and Drug Administration’s audit of the disputable Alzheimer’s medication Aduhelm is presently standing up, contending that the endorsement depended on dodgy science and included problematic coordinated effort among controllers and the medication’s creator. I’m not shocked at the contention since I believe it’s a terrible choice. I think…